IRADIMED (IRMD) Company Report

IRADIMED CORPORATION's Board of Directors declared a special cash dividend of $0.50 per share on its outstanding common stock.
The special dividend is payable on December 30, 2025, to shareholders of record at the close of business on December 17, 2025.
This decision was based on the company's strong financial results, including 17 consecutive quarters of record revenue, and a cash and cash equivalents balance of $56.5 million at the end of the third quarter of 2025, which exceeded its operational and investment needs.

Dec 8, 2025, 1:30 PM

IRadimed Reports Record Q2 2025 Revenue, Raises Full-Year Guidance, and Receives FDA Clearance for New Pump

IRMD

Earnings

Guidance Update

Product Launch

IRadimed reported record Q2 2025 revenues of $20.4 million, a 14% increase over the prior year, marking its 16th consecutive quarter of record revenues. GAAP diluted earnings per share for the quarter increased 18% to $0.45.
The company announced FDA clearance for its new 3870 IV pump systems on May 22, which is projected to be a seminal event driving future growth and contributing to a $100 million revenue run rate by 2026. The new pump's average selling price (ASP) is expected to be approximately 12% higher than the current model.
IRadimed raised its full-year 2025 guidance, now expecting revenues of $80 million - $82.5 million (up from $78 million - $82 million) and GAAP diluted earnings per share of $1.60 - $1.70 (up from $1.55 - $1.65).
For the third quarter of 2025, the company anticipates revenues between $20.5 million - $20.9 million and GAAP diluted earnings per share of $0.41 - $0.45.

Nov 3, 2025, 4:00 PM

IRADIMED CORPORATION Reports Record Q3 2025 Financial Results and Raises Full-Year Guidance

IRMD

Earnings

Guidance Update

Dividends

IRADIMED CORPORATION reported record revenue of $21.2 million for the third quarter of 2025, a 16% increase compared to the same period in 2024, alongside record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47.
The company raised its full-year 2025 guidance, now expecting revenue between $82.5 million and $83.5 million, GAAP diluted EPS of $1.68 to $1.72, and non-GAAP diluted EPS of $1.84 to $1.88.
A regular quarterly cash dividend of $0.17 per share was declared for the fourth quarter of 2025, payable on November 25, 2025.
Limited commercial shipments of the next-generation 3870 MRI-compatible IV infusion pump are anticipated to begin in December 2025, with full U.S. commercialization in the first quarter of 2026.

Nov 3, 2025, 1:30 PM

IRADIMED Reports Record Q3 2025 Financial Results and Raises Full-Year Guidance

IRMD

Earnings

Guidance Update

Dividends

IRADIMED CORPORATION reported record revenue of $21.2 million for the third quarter of 2025, representing a 16% increase compared to the same period in 2024.
The company achieved record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for Q3 2025, increases of 8% and 9% respectively, compared to Q3 2024.
IRADIMED raised its full-year 2025 guidance, now projecting revenue between $82.5 million and $83.5 million and GAAP diluted EPS between $1.68 and $1.72.
A regular quarterly cash dividend of $0.17 per share of common stock was declared for the fourth quarter of 2025, payable on November 25, 2025.